首页 | 本学科首页   官方微博 | 高级检索  
     

Renca 条件培养基转化的调节性T细胞 对小鼠同种免疫的影响
引用本文:滕立臣,刘龙山,苏亚娟,袁小鹏,李军,付倩,陈思阳,王长希. Renca 条件培养基转化的调节性T细胞 对小鼠同种免疫的影响[J]. 中山大学学报(医学科学版), 2010, 31(2)
作者姓名:滕立臣  刘龙山  苏亚娟  袁小鹏  李军  付倩  陈思阳  王长希
作者单位:1. 中山大学附属第一医院器官移植科,广东,广州,510080
2. 南方医科大学附属南方医院检验系,广东,广州,510015
3. 中山大学附属第一医院麻醉科,广东,广州,510080
基金项目:中山大学海外岭南基金 
摘    要: 【目的】 探讨小鼠肾癌细胞株Renca来源的条件培养基能否诱导CD4+ CD25- T细胞转化为具有免疫抑制效能的CD4+ CD25+ Foxp3+ T细胞&#65377; 【方法】 培养Renca提取上清获得条件培养基,将条件培养基与普通培养液按不同比例混合培养小鼠CD4+ CD25- T细胞7 d,以流式细胞仪检测CD4+ CD25+ T细胞和Foxp3+ 细胞的比例;再次分选CD4+ CD25+ T细胞检测其抑制细胞增殖的能力,体内过继性输入观察对移植物存活时间&#65380;局部排斥反应和迟发性超敏反应的影响&#65377;【结果】 与对照组相比,混合培养基显著增加培养体系中CD4+ CD25+ Foxp3+ T细胞的比例(P < 0.05),在一定范围内(≤75%)呈比例依赖关系;随转化性CD4+ CD25+ T细胞比例增加效应T细胞增殖能力减弱;体内输注显著延长移植物的存活时间(P < 0.05),达(29.6 ± 1.4) d,组织学观察显示能明显抑制局部排斥反应&#65377;【结论】 Renca条件培养基能诱导CD4+ CD25- 细胞转化为 CD4+ CD25+ Foxp3+ T细胞,被转化细胞在体内和体外均能发挥免疫抑制作用&#65377;

关 键 词:条件培养基  转化  调节性T细胞  免疫抑制
收稿时间:2010-01-04;

Effect of Converted Regulatory T Cells with Renca Conditioned Media on Suppressive Profile of Allo-immunity in Mice
TENG Li-chen,LIU Long-shan,SU Ya-juan,YUAN Xiao-peng,LI Jun,FU Qian,CHEN Si-yang,WANG Chang-xi. Effect of Converted Regulatory T Cells with Renca Conditioned Media on Suppressive Profile of Allo-immunity in Mice[J]. Journal of Sun Yatsen University(Medical Sciences), 2010, 31(2)
Authors:TENG Li-chen  LIU Long-shan  SU Ya-juan  YUAN Xiao-peng  LI Jun  FU Qian  CHEN Si-yang  WANG Chang-xi
Affiliation:TENG Li-chen1,LIU Long-shan1,SU Ya-juan2,YUAN Xiao-peng1,LI Jun1,FU Qian1,CHEN Si-yang3,WANG Chang-xi1* (1. The Organ Transplantation Department,The First Affiliated Hospital,Sun Yat-sen University,Guangzhou 510080,China,2. Department of Laboratory Medicine,Nanfang Hospital,Nanfang Medical University,Guangzhou 510015,3. Department of Aesthiology,China)
Abstract:[Objective]This study was designed to investigate capability of the conditioned media that originated from Renca cells to convert CIM~+ CD25~- T cells into CD4~+ CD25~+ T cells,which can exert immunosuppressive effect on effector T cells in vitro and in vivo.[Methods]The common media were mixed with the conditioned media at different ratios,and fresh enriched CD4~+ CD25~- T cells with MACS were cultured in mixed media for 7 days.At end-point of culture,the cells were collected and detected phenotypes in flow cytometer.Moreover,we detected immunosuppressive effect of converted CD4~+ CD25~+ T cells on effeetor T cells proliferation in one-way mixed lymphocytes reaction by using CCK-8,and we observed survival time and histology of grafts.The delayed type hypersensitivity was determined 14 days after transplantation.[Results]The mixed media could increase ratio of CD4~+ CD25~+ Foxp3~+ T cells in conditioned media ratio-dependent(P<0.05),compared with control groups,when the mixed media contained no mote than 75% of conditioned media.The converted CD4~+ CD25~+ T cells significantly suppress proliferation of effector T cells in vitro,and prolong survival time of grafts,which were(29.6±1.4)d in converted CD4~+ CD25~+ T cells treated groups(P<0.05),compared with that in untreated groups(9.8±0.6 d)or PBS treated groups(10.9±0.6 d).Moreover,delayed-type hypersensitivity reaction were conducted at day 14 after transplantation in the recipients,and the results showed that less pad swelling in the group treated with converted CD4~+ CD25~+ T cells than other control groups was found,according to measurement of pad swelling.In addition,progressed to complete necrosis of grafts were exhibited in the mice treated with PBS and untreated mice,whereas better healing of grafts and less lymphocytes infiltration were displayed in the mice treated with converted CD4~+ CD25~+ T cells,which were similar to the mice treated with natural regulatory T cells.[Conclusion]The converted CD4~+ CD25~+ T cells with Renca conditioned media play suppressive role in vitro and in vivo.
Keywords:conditioned media  conversion  regulatory T cells  immunosuppression
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《中山大学学报(医学科学版)》浏览原始摘要信息
点击此处可从《中山大学学报(医学科学版)》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号